A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

In the latest close session, Amgen (AMGN) was up +1.69% at $355.30. This move outpaced the S&P 500's daily gain of 1.2%. Elsewhere, the Dow gained 1.79%, while the tech-heavy Nasdaq added 1.52%. Prior ...

If you are wondering whether Amgen’s recent share price puts it on sale or at a premium, and what that really means for your ...

The trial met its primary endpoint, demonstrating a statistically significant 77% proptosis response rate at 24 weeks.

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Healthcare Stocks with Highest Dividends. On April 13, UBS lifted its price ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 Overlooked Growth Stocks to Buy Now. Zai Lab Limited (NASDAQ:ZLAB) is one of ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. New data from a mid-stage study of an Amgen obesity drug showed that it ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...